Stock Ratings / Health Care / SERA / dividends

KEQU (70) BNR (23) XGN (31) TLSI (34) ⌘ Pro Terminal →

Sera Prognostics Inc. (Class A) (SERA) Dividend Safety Gauge & 10-Year DRIP Compounder

$2.06 +1.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.06

Sera Prognostics Inc. (Class A) (SERA) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $81.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.06 (+0.08%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SERA)Realized 20D OHLCV Swing Band: ±6.4%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY SERA SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (33% of score)

FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 49.4 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (30% of score)

20D Institutional Volume Accumulation (±6.4% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.04+1% Next Q

Q2 (-2Q)

Grade E$2.06-1.5% Next Q

Q3 (-1Q)

Grade E$2.03+1.5% Next Q

Current

Grade D-$2.06-7.4% Hist 90D α

Trajectory: E (32) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SERA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SERA currently carries a cautious 40/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.05) and Max Pain ($2.16) forces dealer call-delta covering toward $4.04.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SERA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SERA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SERA)

✓Walkthrough of SERA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SERA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.19%🛡️ HOLDING TREND SUPPORT

2026-10-30O $2.09H $2.10L $2.03C $2.06VOL 86.0K

RES: $2.21SUP: $2.04SMA50: $2.05SMA200: $2.13

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SERA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SERA Butterfly Map → + Track SERA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SERA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SERA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SERA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SERA)

Health Care Rank #646 of 1016 ⚔️ KEQU vs SERA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SERA vs. KEQU, BNR, XGN, TLSI)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sera Prognostics Inc. (Class A) (SERA) ranks #646 by composite RQD confidence (40/100, grade D-) and #685 by equity capitalization ($81.3M). Within this direct 5-issuer industry benchmark cohort, KEQU leads on earnings valuation at 10.1x trailing P/E, while KEQU leads on capital efficiency and profitability with 16.7% ROIC and 28.5% gross margin. KEQU currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with SERA at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SERA ACTIVE Sera Prognostics Inc. (Class A)	D-	40/100	—	-30.0%	-35.0%	+1.48%	$81.3M	Benchmark Subject
KEQU Kewaunee Scientific Corporation	B-	70/100	10.1x	28.5%	16.7%	-3.48%	$97.0M	/kequ-vs-sera →
BNR Burning Rock Biotech Limited	E	23/100	—	74.7%	-35.0%	-9.87%	$116.5M	/bnr-vs-sera →
XGN Exagen Inc.	E	31/100	—	58.3%	-35.0%	+3.57%	$210.8M	/xgn-vs-sera →
TLSI TriSalus Life Sciences Inc.	E	34/100	—	84.6%	-35.0%	-1.78%	$237.7M	/tlsi-vs-sera →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001534969

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sera Prognostics Inc. (Class A) (SERA) reported GAAP revenue of $81.0K (+5.2% vs. FY2024 revenue of $77.0K , and -73.5% cumulative change since FY2023) , GAAP net income of -$31.9M, operating cash flow of -$25.6M, and free cash flow of -$26.3M (-85.0% YoY). On the balance sheet, SERA closed FY2025 with $101.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$81.0K	-$31.9M	-$25.6M	-$26.3M	$101.9M	—
FY2024 (FY)	2024-12-31	$77.0K	-$32.9M	-$14.2M	-$14.2M	$72.6M	—
FY2023 (FY)	2023-12-31	$306.0K	-$36.2M	-$27.2M	-$27.2M	—	—

3. SERA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SERA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Sera Prognostics Inc. (Class A) (NASDAQ: SERA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $2.06 (+1.48% 1D, market cap $81.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SERA ranks #646 in composite RQD confidence.

How does SERA compare to KEQU and BNR in the Health Care sector?

Within the Health Care sector (Medical Specialities), SERA carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, KEQU (Kewaunee Scientific Corporation) holds a B- grade (70/100 RQD, P/E 10.1x, ROIC 16.7%, cap $97.0M) and BNR (Burning Rock Biotech Limited) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $116.5M). Among the 5-stock peer group, KEQU leads on earnings multiple (10.1x) while KEQU leads on capital efficiency (16.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SERA?

Per SERA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001534969), Sera Prognostics Inc. (Class A) generated $81.0K in revenue (+5.2% YoY), -$31.9M in net income, and -$26.3M in free cash flow against $101.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SERA trading relative to its 50-day, 200-day, and 52-week technical levels?

SERA last traded at $2.06 (+1.48% on volume of 18,748 shares), positioning the stock +0.49% above its 50-day simple moving average ($2.05) and -3.29% below its 200-day simple moving average ($2.13). Across its 52-week range of $1.56 to $3.85, SERA sits at the 21.8% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of ±6.4% ($1.93 to $2.19).

SERA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does SERA pay a dividend and is it safe?

Sera Prognostics Inc. (Class A) (SERA) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: SERA RQD Cockpit SERA 12M Forecast SERA Earnings & Move SERA Dividends & DRIP SERA Insiders & 13F SERA Whale Options SERA Profit Sankey SERA News & Why